ISOFLIM: Isotropic resolution fluorescence lifetime imaging of 3D neuron cultures
Lead Research Organisation:
University of Edinburgh
Department Name: Sch of Engineering
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
Neurodegenerative disorders are amongst the most impactful pathologies in modern society, and often feature loss of connectivity within neural circuits. Therefore, understanding the molecular basis of neuronal communication is crucial to elucidate their biological underpinnings. The convergence of bioengineering, stem cell technology and novel imaging reporters has enabled the creation of complex 3D in vitro platforms aimed at the study neuronal function (e.g. Ca2+ dynamics) in live human neurons and glia. These 3D cultures will soon represent the gold standard for in vitro modelling, and therefore it is necessary to ensure the field has the ideal tools to analyse them. Monitoring dynamic molecular processes in 3D cultures requires a quantitative based imaging system capable of acquiring large volumetric image data at high speed with minimal sample perturbation. Currently, such an imaging platform doesn't exist and compromises must be made between fast live imaging, super resolution and detailed quantitative imaging. To bridge this gap we aim to develop a novel functional imaging platform with fast 3D quantitative isotropic imaging to visualise calcium and metabolic dynamics within live neuronal 3D cultures. Building on previous work from the investigators, the system will (i) allow prolonged live imaging in 3D with low toxicity, (ii) enable high time- and spatial resolution, and (iii) provide for quantitative imaging data acquisition (e.g. fluorescence lifetime microscopy, FLIM). Utilising a combination of structured light sheet illumination and synchronous image scanning we will reconstruct selective planes with high spatial and temporal resolution using time-correlated single photon counting detection - giving the ultimate single photon sensitivity for FLIM (ISO-FLIM) in a light sheet geometry. The capability of the imaging system will be tested on a series of experiments with live stem cell derived bioengineered neural cultures with genetically encoded reporters
Planned Impact
The proposed project aims to develop a massively parallel, high-speed isotropic selective plane Fluorescence lifetime imaging system and utilizing FRET based biosensors monitor calcium dynamics, and metabolic activity in 3D bioengineered neuronal cell cultures in real-time. Once the proof-of-concept has been demonstrated this platform can be used to model and monitor other complex biological interactions and mechanisms. One of the main goals is to make it accessible to a wide variety of biological imaging problems from monitoring high-speed protein interaction dynamics to high-content screening applications using FRET readouts of cellular function or perturbation. The work proposed has the potential to have enormous impact to the clinical research community, industry and society.
Research Community
Increasingly sophisticated bio-engineered 3D structures which better mimic the complexity of neuronal circuitry in vivo coupled with the ability to optically interrogate and monitor those structures will undoubtedly have wide appeal to all experimental neuroscience and neuronal cell biology community. Although the biological exemplification for our proposal will be directly relevant for in vitro neuroscience, the protocols and imaging pipeline will immediately be applicable to any live imaging experiments, across fields such as cancer biology, molecular cell biology, microbiology and others (see diverse letters of support). It will also represent an invaluable tool for the bioengineering and tissue engineering community, as it will allow to evaluate dynamic molecular processes in live cells within 3D complex scaffolds.
Industry
From an economic perspective, the development of the MultiFLicity imaging platform will be of great interest to the commercial imaging and life sciences market as well as the pharmaceutical industry. A number of instrumentation companies including Photon Force Ltd, Carl Zeiss Ltd and MSquared (see letters of support) are very interested in the system and would be the immediate beneficiaries(Ameer-Beg and Henderson have collaborative projects with Photon Force Ltd, through EPSRC Quantum hub (Quantic)and Carl Zeiss Ltd (BBSRC iCASE)). Any direct commercialization opportunities for software and hardware solutions that emerge from the research could be explored with these companies.
Pharmaceutical companies will be key longer-term beneficiaries as the activities provide a greater understanding of the consequences of molecular events at the system level leading to more refined drug discovery approaches (Ameer-Beg has key contacts in Pharma through previous collaborations and consultancy (UCB-Pharma and Novatis)). Many of the network members within the Integrative Biological Imaging Network (IBIN), who are strong supporters in this project, have long-term collaborations with the Pharmaceutical industry and will therefore be very well placed provide support to engage with these stakeholders as the network progresses to identify shared interests and collaboration opportunities.
Society
This project will generate a novel imaging platform aimed at dissecting complex molecular dynamics within living cells in 3D, and its applicability will be demonstrated in a series of proof-of-principle experiments based on advanced in vitro bioengineered neuronal cultures. As such, it will enable acquisition of functional data on these cells with speed and spatial resolution unmatched by current systems and therefore generate a wealth of new knowledge on the molecular processes involved in neuronal communication. In turn, this will immediately apply to experimental disease modelling with stem-cell derived in vitro culture, that are currently see their applicability limited by adequate characterization of their functional profile. The SP-FLIM will be an enabling technology to apply new knowledge to neurodegenerative disease modelling, and directly lead to new potential therapies and patient benefit.
Research Community
Increasingly sophisticated bio-engineered 3D structures which better mimic the complexity of neuronal circuitry in vivo coupled with the ability to optically interrogate and monitor those structures will undoubtedly have wide appeal to all experimental neuroscience and neuronal cell biology community. Although the biological exemplification for our proposal will be directly relevant for in vitro neuroscience, the protocols and imaging pipeline will immediately be applicable to any live imaging experiments, across fields such as cancer biology, molecular cell biology, microbiology and others (see diverse letters of support). It will also represent an invaluable tool for the bioengineering and tissue engineering community, as it will allow to evaluate dynamic molecular processes in live cells within 3D complex scaffolds.
Industry
From an economic perspective, the development of the MultiFLicity imaging platform will be of great interest to the commercial imaging and life sciences market as well as the pharmaceutical industry. A number of instrumentation companies including Photon Force Ltd, Carl Zeiss Ltd and MSquared (see letters of support) are very interested in the system and would be the immediate beneficiaries(Ameer-Beg and Henderson have collaborative projects with Photon Force Ltd, through EPSRC Quantum hub (Quantic)and Carl Zeiss Ltd (BBSRC iCASE)). Any direct commercialization opportunities for software and hardware solutions that emerge from the research could be explored with these companies.
Pharmaceutical companies will be key longer-term beneficiaries as the activities provide a greater understanding of the consequences of molecular events at the system level leading to more refined drug discovery approaches (Ameer-Beg has key contacts in Pharma through previous collaborations and consultancy (UCB-Pharma and Novatis)). Many of the network members within the Integrative Biological Imaging Network (IBIN), who are strong supporters in this project, have long-term collaborations with the Pharmaceutical industry and will therefore be very well placed provide support to engage with these stakeholders as the network progresses to identify shared interests and collaboration opportunities.
Society
This project will generate a novel imaging platform aimed at dissecting complex molecular dynamics within living cells in 3D, and its applicability will be demonstrated in a series of proof-of-principle experiments based on advanced in vitro bioengineered neuronal cultures. As such, it will enable acquisition of functional data on these cells with speed and spatial resolution unmatched by current systems and therefore generate a wealth of new knowledge on the molecular processes involved in neuronal communication. In turn, this will immediately apply to experimental disease modelling with stem-cell derived in vitro culture, that are currently see their applicability limited by adequate characterization of their functional profile. The SP-FLIM will be an enabling technology to apply new knowledge to neurodegenerative disease modelling, and directly lead to new potential therapies and patient benefit.
Organisations
People |
ORCID iD |
| Robert Henderson (Principal Investigator) |